These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36694613)

  • 41. Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children.
    Lee PY; Day-Lewis M; Henderson LA; Friedman KG; Lo J; Roberts JE; Lo MS; Platt CD; Chou J; Hoyt KJ; Baker AL; Banzon TM; Chang MH; Cohen E; de Ferranti SD; Dionne A; Habiballah S; Halyabar O; Hausmann JS; Hazen MM; Janssen E; Meidan E; Nelson RW; Nguyen AA; Sundel RP; Dedeoglu F; Nigrovic PA; Newburger JW; Son MBF
    J Clin Invest; 2020 Nov; 130(11):5942-5950. PubMed ID: 32701511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Effect of Biologics in the Treatment of Multisystem Inflammatory Syndrome in Children (Mis-C): A Single-Center Propensity-Score-Matched Study.
    Basaran O; Batu ED; Kaya Akca U; Atalay E; Kasap Cuceoglu M; Sener S; Balık Z; Karabulut E; Kesici S; Karagoz T; Ozsurekci Y; Bilginer Y; Cengiz AB; Ozen S
    Children (Basel); 2023 Jun; 10(6):. PubMed ID: 37371276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Management skin manifestation of multisystem inflammatory syndrome associated with SARS-CoV-2.
    Bayram YE; Yildiz-Sevgi D; Yavuz A; Cancetin M; Gurler MY
    Virol J; 2022 Jan; 19(1):9. PubMed ID: 34991644
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Four Distinct Cases of Multisystem Inflammatory Syndrome in Adults Associated With SARS-CoV-2 Infection at a Community Hospital in New Jersey.
    Vyas C; Dalmacion D; Almeligy A; Juan R; Pernia-Cuberos JD; Obaid A; Heis F; Patel S; Eng MH; Patton CD; Lee A
    Cureus; 2021 Dec; 13(12):e20651. PubMed ID: 35103207
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe Agitation as an Unusual Presentation of Multisystem Inflammatory Syndrome in Children.
    Ghamry MA; Salib K; Henin S; Salah R; Dobs M
    Cureus; 2022 Aug; 14(8):e27621. PubMed ID: 36059320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
    Yang J; Jain S; Capparelli EV; Best BM; Son MB; Baker A; Newburger JW; Franco A; Printz BF; He F; Shimizu C; Hoshino S; Bainto E; Moreno E; Pancheri J; Burns JC; Tremoulet AH
    J Pediatr; 2022 Apr; 243():173-180.e8. PubMed ID: 34953816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
    Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
    Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Challenges in Evaluating Pediatric Fever and Rash in the Era of COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C).
    Jarvill T; Lauber P; Umaru S; Villalobos T; Yaeger SK
    Cureus; 2022 Jan; 14(1):e21764. PubMed ID: 35251835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical features, diagnosis, and outcomes of multisystem inflammatory syndrome in children associated with coronavirus disease 2019.
    Kwak JH; Lee SY; Choi JW;
    Clin Exp Pediatr; 2021 Feb; 64(2):68-75. PubMed ID: 33445833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multisystem Inflammatory Syndrome in an Adult (MIS-A) Successfully Treated with Anakinra and Glucocorticoids.
    Cattaneo P; Volpe A; Cardellino CS; Riccardi N; Bertoli G; Ursini T; Ustalli A; Lodi G; Daroui I; Angheben A
    Microorganisms; 2021 Jun; 9(7):. PubMed ID: 34203277
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Zonulin Antagonist, Larazotide (AT1001), As an Adjuvant Treatment for Multisystem Inflammatory Syndrome in Children: A Case Series.
    Yonker LM; Swank Z; Gilboa T; Senussi Y; Kenyon V; Papadakis L; Boribong BP; Carroll RW; Walt DR; Fasano A
    Crit Care Explor; 2022 Feb; 10(2):e0641. PubMed ID: 35211683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TNF-α blockers for the treatment of Kawasaki disease in children.
    Yamaji N; da Silva Lopes K; Shoda T; Ishitsuka K; Kobayashi T; Ota E; Mori R
    Cochrane Database Syst Rev; 2019 Aug; 8(8):CD012448. PubMed ID: 31425625
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensive Care Needs and Short-Term Outcome of Multisystem Inflammatory Syndrome in Children (MIS-C): Experience from North India.
    Angurana SK; Awasthi P; Thakur A; Randhawa MS; Nallasamy K; Kumar MR; Naganur S; Kumar M; Goyal K; Ghosh A; Bansal A; Jayashree M
    J Trop Pediatr; 2021 Jul; 67(3):. PubMed ID: 34170328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Who Would Have Predicted Multisystem Inflammatory Syndrome in Children?
    Reiff DD; Cron RQ
    Curr Rheumatol Rep; 2022 Jan; 24(1):1-11. PubMed ID: 35150412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of sildenafil and high-dose anakinra in an MIS-C patient with pulmonary vasculitis: A case report.
    La Torre F; Calabrese G; Signorile K; Bizzoco F; Mastrorilli C; Strippoli A; Amato D; Carella F; Vairo U; Giordano P; Milella L; Cardinale F
    Front Pediatr; 2022; 10():1015617. PubMed ID: 36644405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain.
    García-Salido A; de Carlos Vicente JC; Belda Hofheinz S; Balcells Ramírez J; Slöcker Barrio M; Leóz Gordillo I; Hernández Yuste A; Guitart Pardellans C; Cuervas-Mons Tejedor M; Huidobro Labarga B; Vázquez Martínez JL; Gutiérrez Jimeno M; Oulego-Erróz I; Trastoy Quintela J; Medina Monzón C; Medina Ramos L; Holanda Peña MS; Gil-Antón J; Sorribes Ortí C; Flores González JC; Hernández Palomo RM; Sánchez Ganfornina I; Fernández Romero E; García-Besteiro M; López-Herce Cid J; González Cortés R;
    Crit Care; 2020 Nov; 24(1):666. PubMed ID: 33243303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic treatment regimens in small n, sequential, multiple assignment, randomized trials: An application in focal segmental glomerulosclerosis.
    Chao YC; Trachtman H; Gipson DS; Spino C; Braun TM; Kidwell KM
    Contemp Clin Trials; 2020 May; 92():105989. PubMed ID: 32200006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early is superior to late plasma exchange for severe multisystem inflammatory syndrome in children.
    Katlan B; Kesici S; Karacanoğlu D; Oygar PD; Ünal Yüksekgönül A; Şener S; Aykan HH; Özsurekçi Y; Özen S; Bayrakci B
    J Clin Apher; 2022 Jun; 37(3):281-291. PubMed ID: 35174897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.